Using in vitro genetic gain- or loss-of-function studies, they found that overexpression of RHOJ lead to increased tumor cell survival following chemotherapy, whereas knockdown of RHOJ sensitized tumor cells to chemotherapy. Here, RHOJ is linked to neoplasm.